Skip to main content
. 2019 Jan 29;8(2):96. doi: 10.3390/cells8020096

Table 1.

Demographics and clinical data of male patients with Parkinson disease and of controls.

Participants Characteristics Controls
N = 35
PD
N = 35
p-Value Akinetic-Rigid PD
N = 19
Mixed PD
N = 16
p-Value
Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Age [years] 55 (50;66) 59 (54; 66) 0.14 60 (54; 67) 59 (55; 66) 0.64
Age at diagnosis [years] 54 (49; 60) 52 (47; 60) 55 (53; 59) 0.37
PD duration [years] 4.7 (2.5; 7.7) 6.0 (3.6; 8.8) 3.5 (1.5; 5.4) 0.03
MDS-UPDRS3
total score;
range (0–132)
1 (0; 2) 34 (24; 43) <0.0001 34 (24; 43) 34.5 (25.5; 45.5) 0.95
MDS-UPDRS3
rigidity subscore;
range (0–20)
0 (0; 0) 7 (3; 8) <0.0001 7 (5; 8) 4 (2.5; 8) 0.10
Tapping hits
(left or more affected hand)
186 (180; 205) 164 (134; 184) 0.0001 163 (143; 178) 176 (126; 190) 0.80
Tremor amplitude (mm)
(left or more affected hand)
0.9 (0.7; 1.1) 1.1 (0.8; 1.3) 0.019 1.1 (0.8; 1.2) 1.2 (0.8; 1.9) 0.26
N (%) N (%) N (%) N %
Education
Low 8 (22.9) 17 (48.6) 0.08 12 (63.2) 5 (31.3) 0.06
Medium 8 (22.9) 6 (17.1) 4 (21.1) 2 (12.5)
High 19 (54.3) 12 (34.3) 3 (15.8) 9 (56.3)
Clinically more affected side
Left 12 (34.3) 5 (26.3) 7 (43.8) 0.24
Right 14 (40.0) 7 (36.8) 7 (43.8
No preference 9 (25.7) 7 (36.8) 2 (12.5)

Abbreviations: IQR: inter-quartile range (25th; 75th percentile), PD: Parkinson’s disease, MDS-UPDRS3: Movement Disorder Society-Sponsored Revision of the Unified Parkinson Disease Rating Scale part III, p-value obtained by Kruskal–Wallis test or χ2 test (significant effects marked in bold and marginal effects marked in italic).